Dianhydrogalactitol is under clinical development by Kintara Therapeutics and currently in Phase III for Glioblastoma Multiforme (GBM). According to GlobalData, Phase III drugs for Glioblastoma Multiforme (GBM) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Dianhydrogalactitol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dianhydrogalactitol (VAL-083/Dag) is under development for the treatment of MGMT-unmethylated GBM, diffuse intrinsic pontine glioma, bevacizumab-naive recurrent glioblastoma multiforme, medulloblastoma, high-grade glioma, relapsed and refractory non-small cell lung cancer, cervical cancer, ovarian cancers, brain tumour and other solid tumours (bladder cancer and head and neck cancer). It is formulated as the injection for intravenous administration. It was under development for recurrent glioblastoma multiforme (GBM), gliosarcoma.
Kintara Therapeutics overview
Kintara Therapeutics (DelMar) formerly DelMar Pharmaceuticals Inc, is a clinical stage drug development bio pharmaceutical company. It is engaged in the development and commercialization of new cancer therapies. The company offers VAL-083, a small molecule chemotherapy used for the treatment of refractory glioblastoma multiforme(GMB) of brain cancer. Kintara also explores VAL-083 as a therapy for solid tumors and front-line GBM including ovarian cancer and non-small cell lung cancer (NSCLC). The company offers its produts and services to lung cancer, ovarian cancer, chronic myeloid leukemia, brain cancers, and lung cancer. Kintara provides warrants services, pre-clinical testing, and clinical trials, among others. It also conducts research and development on cancer indications. It has operations in the US and Canada. Kintara Pharmaceuticals is headquartered in San Diego, California, United States.
For a complete picture of Dianhydrogalactitol’s drug-specific PTSR and LoA scores, buy the report here.